Biology:Lipoprotein lipase

From HandWiki
Short description: Mammalian protein found in Homo sapiens


A representation of the 3D structure of the protein myoglobin showing turquoise α-helices.
Generic protein structure example
Lipoprotein lipase
Identifiers
EC number3.1.1.34
CAS number9004-02-8
Databases
IntEnzIntEnz view
BRENDABRENDA entry
ExPASyNiceZyme view
KEGGKEGG entry
MetaCycmetabolic pathway
PRIAMprofile
PDB structuresRCSB PDB PDBe PDBsum
Gene OntologyAmiGO / QuickGO

Lipoprotein lipase (LPL) (EC 3.1.1.34, systematic name triacylglycerol acylhydrolase (lipoprotein-dependent)) is a member of the lipase gene family, which includes pancreatic lipase, hepatic lipase, and endothelial lipase. It is a water-soluble enzyme that hydrolyzes triglycerides in lipoproteins, such as those found in chylomicrons and very low-density lipoproteins (VLDL), into two free fatty acids and one monoacylglycerol molecule:

triacylglycerol + H2O = diacylglycerol + a carboxylate

It is also involved in promoting the cellular uptake of chylomicron remnants, cholesterol-rich lipoproteins, and free fatty acids.[1][2][3] LPL requires ApoC-II as a cofactor.[4][5]

LPL is attached to the luminal surface of endothelial cells in capillaries by the protein glycosylphosphatidylinositol HDL-binding protein 1 (GPIHBP1) and by heparan sulfated peptidoglycans.[6] It is most widely distributed in adipose, heart, and skeletal muscle tissue, as well as in lactating mammary glands.[7][8][9]

Synthesis

In brief, LPL is secreted from heart, muscle and adipose parenchymal cells as a glycosylated homodimer, after which it is translocated through the extracellular matrix and across endothelial cells to the capillary lumen. After translation, the newly synthesized protein is glycosylated in the endoplasmic reticulum. The glycosylation sites of LPL are Asn-43, Asn-257, and Asn-359.[1] Glucosidases then remove terminal glucose residues; it was once believed that this glucose trimming is responsible for the conformational change needed for LPL to form homodimers and become catalytically active.[1][9][10][11] In the Golgi apparatus, the oligosaccharides are further altered to result in either two complex chains, or two complex and one high-mannose chain.[1][9] In the final protein, carbohydrates account for about 12% of the molecular mass (55-58 kDa).[1][9][12]

Homodimerization is required before LPL can be secreted from cells.[12][13] After secretion, LPL is carried across endothelial cells and presented into the capillary lumen by the protein glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.[14][15]

Structure

Crystal structures of LPL complexed with GPIHBP1 have been reported.[16][17] LPL is composed of two distinct regions: the larger N-terminus domain that contains the lipolytic active site, and the smaller C-terminus domain. These two regions are attached by a peptide linker. The N-terminus domain has an α/β hydrolase fold, which is a globular structure containing a central β sheet surrounded by α helices. The C-terminus domain is a β sandwich formed by two β sheet layers, and resembles an elongated cylinder.

Mechanism

Image 1: The proposed LPL homodimer structure; N-terminal domains in blue, C-terminal domains in orange. Lid region blocking the active site is shown in dark blue. Triglyceride binds to the C-terminal domain and the lid region, inducing a conformation change in LPL to make the active site accessible.

The active site of LPL is composed of the conserved Ser-132, Asp-156, and His-241 triad. Other important regions of the N-terminal domain for catalysis includes an oxyanion hole (Trp-55, Leu-133), a lid region (residues 216-239), as well as a β5 loop (residues 54-64).[1][7][11] The ApoC-II binding site is currently unknown, but it is predicted that residues on both N-and C-terminal domains are necessary for this interaction to occur. The C-terminal domain appears to confer LPL’s substrate specificity; it has a higher affinity for large triacylglyceride-rich lipoproteins than cholesterol-rich lipoproteins.[18] The C-terminal domain is also important for binding to LDL’s receptors.[19] Both the N-and C-terminal domains contain heparin binding sites distal to the lipid binding sites; LPL therefore serves as a bridge between the cell surface and lipoproteins. Importantly, LPL binding to the cell surface or receptors is not dependent on its catalytic activity.[20]

The LPL non-covalent homodimer has a head-to-tail arrangement of the monomers. The Ser/Asp/His triad is in a hydrophobic groove that is blocked from solvent by the lid.[1][7] Upon binding to ApoC-II and lipid in the lipoprotein, the C-terminal domain presents the lipid substrate to the lid region. The lipid interacts with both the lid region and the hydrophobic groove at the active site; this causes the lid to move, providing access to the active site. The β5 loop folds back into the protein core, bringing one of the electrophiles of the oxyanion hole into position for lipolysis.[1] The glycerol backbone of the lipid is then able to enter the active site and is hydrolyzed.

Two molecules of ApoC-II can attach to each LPL dimer.[21] It is estimated that up to forty LPL dimers may act simultaneously on a single lipoprotein.[1] In regard to kinetics, it is believed that release of product into circulation is the rate-limiting step in the reaction.[7]

Function

LPL gene encodes lipoprotein lipase, which is expressed in the heart, muscle, and adipose tissue.[22][23] LPL functions as a homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. Through catalysis, VLDL is converted to IDL and then to LDL. Severe mutations that cause LPL deficiency result in type I hyperlipoproteinemia, while less extreme mutations in LPL are linked to many disorders of lipoprotein metabolism.[24]

Regulation

LPL is controlled transcriptionally and posttranscriptionally.[25] The circadian clock may be important in the control of Lpl mRNA levels in peripheral tissues.[26]

LPL isozymes are regulated differently depending on the tissue. For example, insulin is known to activate LPL in adipocytes and its placement in the capillary endothelium. By contrast, insulin has been shown to decrease expression of muscle LPL.[27] Muscle and myocardial LPL is instead activated by glucagon and adrenaline. This helps to explain why during fasting, LPL activity increases in muscle tissue and decreases in adipose tissue, whereas after a meal, the opposite occurs.[1][9]

Consistent with this, dietary macronutrients differentially affect adipose and muscle LPL activity. After 16 days on a high-carbohydrate or a high-fat diet, LPL activity increased significantly in both tissues 6 hours after a meal of either composition, but there was a significantly greater rise in adipose tissue LPL in response to the high-carbohydrate diet compared to the high-fat diet. There was no difference between the two diets' effects on insulin sensitivity or fasting LPL activity in either tissue.[28]

The concentration of LPL displayed on endothelial cell surface cannot be regulated by endothelial cells, as they neither synthesize nor degrade LPL. Instead, this regulation occurs by managing the flux of LPL arriving at the lipolytic site and by regulating the activity of LPL present on the endothelium. A key protein involved in controlling the activity of LPL is ANGPTL4, which serves as a local inhibitor of LPL. Induction of ANGPTL4 accounts for the inhibition of LPL activity in white adipose tissue during fasting. Growing evidence implicates ANGPTL4 in the physiological regulation of LPL activity in a variety of tissues.[29]

An ANGPTL3-4-8 model was proposed to explain the variations of LPL activity during the fed-fast cycle.[30] Specifically, feeding induces ANGPTL8, activating the ANGPTL8–ANGPTL3 pathway, which inhibits LPL in cardiac and skeletal muscles, thereby making circulating triglycerides available for uptake by white adipose tissue, in which LPL activity is elevated owing to diminished ANGPTL4; the reverse is true during fasting, which suppresses ANGPTL8 but induces ANGPTL4, thereby directing triglycerides to muscles. The model suggests a general framework for how triglyceride trafficking is regulated.[30]

Clinical significance

Lipoprotein lipase deficiency leads to hypertriglyceridemia (elevated levels of triglycerides in the bloodstream).[31] In mice, overexpression of LPL has been shown to cause insulin resistance,[32][33] and to promote obesity.[26]

A high adipose tissue LPL response to a high-carbohydrate diet may predispose toward fat gain. One study reported that subjects gained more body fat over the next four years if, after following a high-carbohydrate diet and partaking of a high-carbohydrate meal, they responded with an increase in adipose tissue LPL activity per adipocyte, or a decrease in skeletal muscle LPL activity per gram of tissue.[34]

LPL expression has been shown to be a prognostic predictor in Chronic lymphocytic leukemia.[35] In this haematological disorder, LPL appears to provide fatty acids as an energy source to malignant cells.[36] Thus, elevated levels of LPL mRNA or protein are considered to be indicators of poor prognosis.[37][38][39][40][41][42][43][44][45][46]

Interactions

Lipoprotein lipase has been shown to interact with LRP1.[47][48][49] It is also a ligand for α2M, GP330, and VLDL receptors.[19] LPL has been shown to be a ligand for LRP2, albeit at a lower affinity than for other receptors; however, most of the LPL-dependent VLDL degradation can be attributed to the LRP2 pathway.[19] In each case, LPL serves as a bridge between receptor and lipoprotein. While LPL is activated by ApoC-II, it is inhibited by ApoCIII.[7]

In other organisms

The LPL gene is highly conserved across vertebrates. Lipoprotein lipase is involved in lipid transport in the placentae of live bearing lizards (Pseudemoia entrecasteauxii).[50]

Interactive pathway map

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 "Lipoprotein lipase: structure, function, regulation, and role in disease". J. Mol. Med. 80 (12): 753–69. December 2002. doi:10.1007/s00109-002-0384-9. PMID 12483461. 
  2. ↑ "Lipoprotein lipase mediates an increase in the selective uptake of high density lipoprotein-associated cholesteryl esters by hepatic cells in culture". J. Lipid Res. 39 (7): 1335–48. July 1998. doi:10.1016/S0022-2275(20)32514-1. PMID 9684736. 
  3. ↑ "Mutagenesis in four candidate heparin binding regions (residues 279-282, 291-304, 390-393, and 439-448) and identification of residues affecting heparin binding of human lipoprotein lipase". J. Lipid Res. 35 (11): 2049–59. November 1994. doi:10.1016/S0022-2275(20)39951-X. PMID 7868983. 
  4. ↑ "Apolipoprotein C-II is a novel substrate for matrix metalloproteinases". Biochem. Biophys. Res. Commun. 339 (1): 47–54. January 2006. doi:10.1016/j.bbrc.2005.10.182. PMID 16314153. 
  5. ↑ "Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II". Proc. Natl. Acad. Sci. U.S.A. 74 (11): 4848–51. November 1977. doi:10.1073/pnas.74.11.4848. PMID 270715. Bibcode: 1977PNAS...74.4848K. 
  6. ↑ "Heparan sulfate and heparin interactions with proteins". Journal of the Royal Society, Interface 12 (110): 0589. September 2015. doi:10.1098/rsif.2015.0589. PMID 26289657. 
  7. ↑ 7.0 7.1 7.2 7.3 7.4 "Structure and functional properties of lipoprotein lipase". Biochimica et Biophysica Acta 1123 (1): 1–17. January 1992. doi:10.1016/0005-2728(92)90119-M. PMID 1730040. https://epub.ub.uni-muenchen.de/3772/1/82.pdf. 
  8. ↑ "The lipase gene family". Journal of Lipid Research 43 (7): 993–9. July 2002. doi:10.1194/jlr.R200007-JLR200. PMID 12091482. 
  9. ↑ 9.0 9.1 9.2 9.3 9.4 "Regulation of the synthesis, processing and translocation of lipoprotein lipase". The Biochemical Journal 287 ( Pt 2) (2): 337–47. October 1992. doi:10.1042/bj2870337. PMID 1445192. 
  10. ↑ "The relation between glycosylation and activity of guinea pig lipoprotein lipase". J. Biol. Chem. 264 (7): 4195–200. March 1989. doi:10.1016/S0021-9258(19)84982-7. PMID 2521859. 
  11. ↑ 11.0 11.1 "Lipoprotein lipase domain function". J. Biol. Chem. 269 (14): 10319–23. April 1994. doi:10.1016/S0021-9258(17)34063-2. PMID 8144612. 
  12. ↑ 12.0 12.1 "Biosynthesis of lipoprotein lipase in cultured mouse adipocytes. II. Processing, subunit assembly, and intracellular transport". J. Biol. Chem. 264 (22): 13206–16. August 1989. doi:10.1016/S0021-9258(18)51616-1. PMID 2753912. 
  13. ↑ "The role of glucose and glycosylation in the regulation of lipoprotein lipase synthesis and secretion in rat adipocytes". J. Biol. Chem. 264 (6): 3177–82. February 1989. doi:10.1016/S0021-9258(18)94047-0. PMID 2644281. 
  14. ↑ "Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons.". Cell Metabolism 5 (4): 279–291. 2007. doi:10.1016/j.cmet.2007.02.002. PMID 17403372. 
  15. ↑ "GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries". Cell Metabolism 12 (1): 42–52. July 2010. doi:10.1016/j.cmet.2010.04.016. PMID 20620994. 
  16. ↑ PDB: 6E7K​; "Structure of the lipoprotein lipase-GPIHBP1 complex that mediates plasma triglyceride hydrolysis". Proceedings of the National Academy of Sciences of the United States of America 116 (5): 1723–1732. January 2019. doi:10.1073/pnas.1817984116. PMID 30559189. Bibcode: 2019PNAS..116.1723B. 
  17. ↑ PDB: 6OAU, 6OAZ, 6OB0​; "Structure of lipoprotein lipase in complex with GPIHBP1". Proceedings of the National Academy of Sciences of the United States of America 116 (21): 10360–10365. May 2019. doi:10.1073/pnas.1820171116. PMID 31072929. Bibcode: 2019PNAS..11610360A. 
  18. ↑ "Contribution of the carboxy-terminal domain of lipoprotein lipase to interaction with heparin and lipoproteins". Biochem. Biophys. Res. Commun. 271 (1): 15–21. April 2000. doi:10.1006/bbrc.2000.2530. PMID 10777674. 
  19. ↑ 19.0 19.1 19.2 "Lipoprotein lipase binds to low density lipoprotein receptors and induces receptor-mediated catabolism of very low density lipoproteins in vitro". J. Biol. Chem. 271 (29): 17073–80. July 1996. doi:10.1074/jbc.271.29.17073. PMID 8663292. 
  20. ↑ "Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein". Proc. Natl. Acad. Sci. U.S.A. 88 (19): 8342–6. October 1991. doi:10.1073/pnas.88.19.8342. PMID 1656440. Bibcode: 1991PNAS...88.8342B. 
  21. ↑ "Identification of a lipoprotein lipase cofactor-binding site by chemical cross-linking and transfer of apolipoprotein C-II-responsive lipolysis from lipoprotein lipase to hepatic lipase". J. Biol. Chem. 278 (25): 23027–35. June 2003. doi:10.1074/jbc.M300315200. PMID 12682050. 
  22. ↑ Protein Atlas, Protein Atlas. "Tissue expression of LPL - Summary - The Human Protein Atlas". The Human Protein Atlas. https://www.proteinatlas.org/ENSG00000175445-LPL/tissue. 
  23. ↑ Gene Cards, Gene Cards. "Human Gene Database". GeneCardsSuite. https://www.genecards.org/cgi-bin/carddisp.pl?gene=LPL. 
  24. ↑ "Entrez Gene: LPL lipoprotein lipase". https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4023. 
  25. ↑ "Lipoprotein lipase: from gene to obesity.". Am J Physiol Endocrinol Metab 297 (2): E271–88. 2009. doi:10.1152/ajpendo.90920.2008. PMID 19318514. 
  26. ↑ 26.0 26.1 "The nuclear receptor REV-ERBα is required for the daily balance of carbohydrate and lipid metabolism.". FASEB J 26 (8): 3321–35. 2012. doi:10.1096/fj.12-208751. PMID 22562834. 
  27. ↑ "Effects of insulin and exercise on muscle lipoprotein lipase activity in man and its relation to insulin action". J. Clin. Invest. 84 (4): 1124–9. October 1989. doi:10.1172/JCI114275. PMID 2677048. 
  28. ↑ "Effect of dietary macronutrient composition on tissue-specific lipoprotein lipase activity and insulin action in normal-weight subjects". Am. J. Clin. Nutr. 68 (2): 296–302. August 1998. doi:10.1093/ajcn/68.2.296. PMID 9701186. http://ajcn.nutrition.org/content/68/2/296.full.pdf. 
  29. ↑ "Regulation of lipoprotein lipase by Angptl4.". Trends Endocrinol. Metab. 25 (3): 146–155. 2014. doi:10.1016/j.tem.2013.12.005. PMID 24397894. 
  30. ↑ 30.0 30.1 "The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking.". Open Biol. 6 (4): 150272. April 2016. doi:10.1098/rsob.150272. PMID 27053679. 
  31. ↑ "A novel complex deletion-insertion mutation mediated by Alu repetitive elements leads to lipoprotein lipase deficiency". Mol. Genet. Metab. 92 (3): 229–33. November 2007. doi:10.1016/j.ymgme.2007.06.018. PMID 17706445. 
  32. ↑ "Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance.". Diabetes 50 (5): 1064–8. 2001. doi:10.2337/diabetes.50.5.1064. PMID 11334409. 
  33. ↑ "Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance.". Proc Natl Acad Sci U S A 98 (13): 7522–7. 2001. doi:10.1073/pnas.121164498. PMID 11390966. Bibcode: 2001PNAS...98.7522K. 
  34. ↑ "Tissue-specific responses of lipoprotein lipase to dietary macronutrient composition as a predictor of weight gain over 4 years". Obesity (Silver Spring) 20 (5): 1006–11. May 2012. doi:10.1038/oby.2011.372. PMID 22262159. 
  35. ↑ "Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression". Molecules 22 (12): 2083. December 2017. doi:10.3390/molecules22122083. PMID 29206143. 
  36. ↑ "Metabolism pathways in chronic lymphocytic leukemia". Leukemia & Lymphoma 57 (4): 758–65. 8 December 2015. doi:10.3109/10428194.2015.1106533. PMID 26643954. 
  37. ↑ "The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia". Blood 106 (2): 650–7. July 2005. doi:10.1182/blood-2004-08-3344. PMID 15802535. 
  38. ↑ "High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia". Leukemia 19 (7): 1216–23. July 2005. doi:10.1038/sj.leu.2403748. PMID 15858619. 
  39. ↑ "The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia". Haematologica 91 (1): 56–63. January 2006. PMID 16434371. 
  40. ↑ "Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia". Leukemia & Lymphoma 47 (6): 1053–61. June 2006. doi:10.1080/10428190500464161. PMID 16840197. 
  41. ↑ "Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity". Leukemia Research 34 (3): 301–6. March 2010. doi:10.1016/j.leukres.2009.07.032. PMID 19709746. 
  42. ↑ "LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia". Haematologica 96 (8): 1153–60. August 2011. doi:10.3324/haematol.2010.039396. PMID 21508119. 
  43. ↑ "Lipoprotein lipase in chronic lymphocytic leukaemia - strong biomarker with lack of functional significance". Leukemia Research 37 (6): 631–6. June 2013. doi:10.1016/j.leukres.2013.02.008. PMID 23478142. 
  44. ↑ "Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia". Pathology & Oncology Research 23 (1): 165–171. January 2017. doi:10.1007/s12253-016-0132-z. PMID 27757836. 
  45. ↑ "LPL protein in Chronic Lymphocytic Leukaemia have different origins in Mutated and Unmutated patients. Advances for a new prognostic marker in CLL". British Journal of Haematology 182 (4): 521–525. August 2018. doi:10.1111/bjh.15427. PMID 29953583. 
  46. ↑ "Lipoprotein lipase in chronic lymphocytic leukemia: function and prognostic implications". European Journal of Haematology 97 (5): 409–415. November 2016. doi:10.1111/ejh.12789. PMID 27504855. 
  47. ↑ "The carboxyl-terminal domain of lipoprotein lipase binds to the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) and mediates binding of normal very low density lipoproteins to LRP". J. Biol. Chem. 269 (12): 8653–8. March 1994. doi:10.1016/S0021-9258(17)37017-5. PMID 7510694. 
  48. ↑ "A carboxyl-terminal fragment of lipoprotein lipase binds to the low density lipoprotein receptor-related protein and inhibits lipase-mediated uptake of lipoprotein in cells". J. Biol. Chem. 269 (50): 31747–55. December 1994. doi:10.1016/S0021-9258(18)31759-9. PMID 7989348. 
  49. ↑ "The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor binds and mediates catabolism of bovine milk lipoprotein lipase". J. Biol. Chem. 267 (36): 25764–7. December 1992. doi:10.1016/S0021-9258(18)35675-8. PMID 1281473. 
  50. ↑ "Placental lipoprotein lipase (LPL) gene expression in a placentotrophic lizard, Pseudemoia entrecasteauxii". Journal of Experimental Zoology Part B: Molecular and Developmental Evolution 320 (7): 465–70. November 2013. doi:10.1002/jez.b.22526. PMID 23939756. 

Further reading

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Lipoprotein_lipase&oldid=3499977"